A Phase I/II Study Protocol of a Novel Neoadjuvant ‘PRaG’ Regimen (Radiotherapy, GM-CSF, and Cadonilimab) with AG Chemotherapy to Improve Resectability in Locally Advanced Pancreatic Ductal Adenocarcinoma: The NeoPRAG Study
Technology in Cancer Research & Treatment · 2025
DOI: 10.1177/15330338251399255 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Technology in Cancer Research & Treatment, 2025. Verfasst von Meiling Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center of PRaG Therapy, The Second Affiliated Hospital of Soochow University, Suzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Neoadjuvant Therapy, Pancreatic Neoplasms, Granulocyte-Macrophage Colony-Stimulating Factor. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the National Natural Science Foundation of China, Gusu Talent Program, Suzhou Gusu Health Talent Program.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with a dismal prognosis, largely due to late diagnosis at an unresectable stage. Neoadjuvant therapy aims to downstage tumors to achieve surgical resectability, but efficacy is limited. The immunosuppressive tumor microenvironment (TME) of PDAC renders it resistant to conventional immunotherapy. To evaluate the safety and efficacy of a novel neoadjuvant regimen (the NeoPRAG protocol) for patients with locally PDAC. The primary goal is to determine the regimen's safety in Phase I and the 1-year overall survival rate in Phase II, with the ultimate aim of improving surgical resectability and survival outcomes.
Methods
The NeoPRAG study is a prospective single-center, open-label, Phase I/II clinical trial designed to evaluate a neoadjuvant regimen in patients with locally advanced (borderline resectable or unresectable) PDAC. The treatment strategy combines the “PRaG” concept (hypofractionated Radiotherapy and Granulocyte-Macrophage Colony-Stimulating Factor [GM-CSF]) with dual checkpoint blockade and chemotherapy. The Phase I portion will determine the safety, tolerability, and recommended Phase II dose (RP2D) of the radiotherapy component using a 3 + 3 dose-escalation design. The Phase II portion will assess the preliminary efficacy of the regimen, with the primary endpoint being the 1-year overall survival (OS) rate. Secondary endpoints include objective response rate (ORR), R0 resection rate, progression-free survival (PFS), and a comprehensive panel of translational biomarkers. The study is planned to commence in December 2023. Patient enrollment and follow-up are expected to be completed by November 2026, with final data analysis scheduled for December 2026.
Conclusion
The NeoPRAG protocol outlines an innovative, multi-modal strategy that confronts the immunological barriers of pancreatic cancer. It is hypothesized that this combination will synergistically remodel the TME, induce a potent anti-tumor immune response, and ultimately improve the survival landscape for this devastating disease by increasing conversion to resectability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of PRaG Therapy, The Second Affiliated Hospital of Soochow University, Suzhou, China.
- Center for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University, Suzhou, China.
- Laboratory for Combined Radiotherapy and Immunotherapy of Cancer, The Second Affiliated Hospital of Soochow University, Suzhou, China.
- Department of General Surgery, Second Affiliated Hospital, Soochow University, Suzhou, China.
- Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Soochow University.
ORCID-Profile: Liyuan Zhang
Förderung
- the National Natural Science Foundation of China
- Gusu Talent Program
- Suzhou Gusu Health Talent Program
- The Scientific Research Program for Young Talents of China National Nuclear Corporation. Postgraduate Research & Practice Innovation Program of Jiangsu Province
- Suzhou Applied Basic Research (Medical and Health) Science and Technology Innovation Project
- Open project of the State Key Laboratory of Radiology and Radiation Protection of Soochow University
- Open Project of State Key Laboratory of Radiation Medicine and Protection of Soochow University
- Multi-center Clinical Research Project for Major Diseases in Suzhou
Zitieren
APA
Xu, M., Zhang, J., Kong, Y., Xing, P., Zhao, X., Chen, R., Pu, Y., Chen, W., & Zhang, L. (2025). A Phase I/II Study Protocol of a Novel Neoadjuvant ‘PRaG’ Regimen (Radiotherapy, GM-CSF, and Cadonilimab) with AG Chemotherapy to Improve Resectability in Locally Advanced Pancreatic Ductal Adenocarcinoma: The NeoPRAG Study. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338251399255
Vancouver
Xu M, Zhang J, Kong Y, Xing P, Zhao X, Chen R, et al. A Phase I/II Study Protocol of a Novel Neoadjuvant ‘PRaG’ Regimen (Radiotherapy, GM-CSF, and Cadonilimab) with AG Chemotherapy to Improve Resectability in Locally Advanced Pancreatic Ductal Adenocarcinoma: The NeoPRAG Study. Technology in Cancer Research & Treatment. 2025. doi:10.1177/15330338251399255
BibTeX
@article{Xu2025,
author = {Xu, Meiling and Zhang, Junjun and Kong, Yuehong and Xing, Pengfei and Zhao, Xiangrong and Chen, Rongzheng and Pu, Yuwei and Chen, Wei and Zhang, Liyuan},
title = {A Phase I/II Study Protocol of a Novel Neoadjuvant ‘PRaG’ Regimen (Radiotherapy, GM-CSF, and Cadonilimab) with AG Chemotherapy to Improve Resectability in Locally Advanced Pancreatic Ductal Adenocarcinoma: The NeoPRAG Study},
journal = {Technology in Cancer Research & Treatment},
year = {2025},
doi = {10.1177/15330338251399255}
}
EUVIMED